medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Rapid spread of the SARS-CoV-2 δ variant in the area of Paris (France) in June 2021

Samuel Alizon[1,+], Stéphanie Haim-Boukobza[2], Vincent Foulongne[3], Laura Verdurme[2], Sabine Trombert-Paolantoni[2], Emmanuel Lecorche[2], Bénédicte Roquebert[2], Mircea T. Sofonea[1]

[1] MIVEGEC, CNRS, IRD, Université de Montpellier, Montpellier, France
[2] Laboratoire Cerba, Saint Ouen L'Aumône, France
[3] Laboratoire de Virologie, CHU de Montpellier, France * Corresponding author: samuel.alizon@cnrs.fr

Abstract

Analysing 5,061 variant-specific tests performed on SARS-CoV-2 positive samples collected in France between 31 May and 8 June 2021 reveals a rapid growth of the δ variant in the Île-de-France region. The next weeks will prove decisive but the magnitude of the estimated transmission advantage (with a 95% confidence interval between 67 and 120%) could represent a major challenge for public health authorities.

The evolution of SARS-CoV-2 variants has caused major epidemics in the United Kingdom (UK) [1, 2], Brazil [3], or South-Africa [4]. In May 2021, the δ variant, which was first detected in India, was associated with an epidemic rebound in the United Kingdom (UK) [5]. According to Public Health England [6], this variant has a transmission advantage of approximately 66% (95% confidence interval (CI): [28,113]%) over the α variant based on within-household transmission. It is also slightly more prone to immune evasion [7]. As shown in 2021 with the emergence of the α variant, there is a two-month shift between the epidemic situation in France and the UK [8, 9]. Therefore, it is timely to investigate the potential early spread of the δ variant to devise appropriate public health responses.

We analysed 5,061 RT-PCR variant-specific screening tests (VirSNiP assay, TIB Molbiol, Genova, Italy) performed on samples collected in France between 31 May and 8 June 2021 that were tested positive for SARS-CoV-2. The assay screens for the presence of the E484K, the E484Q, and the L425R mutations (Supplementary Methods). A 484K+/484Q-/452R- profile is consistent with the B.1.351, P.1, and B.1.525 Pango lineages (i.e. variants β, γ, and η), whereas a 484K-/484Q-/452R+ profile is consistent with the B.1.617.2 lineage (i.e. variant δ) [10]. These tests originated from different French regions, with a dominance of the Île-de-France and the Paris area (2,443/5,061 tests, i.e. 48%). Most of the tests originated from non-hospitalised individuals (4,775/5,061 tests, i.e. 94%) (Supplementary Table S1).

Variant-screening test results

As shown in Table 1, using a multinomial regression model as in [11], we found that samples bearing the L452R mutation and neither the E484K nor the E484Q mutation, i.e. consistent with the variant δ,

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

tended to increase in the Île-de-France region compared to our reference (samples without any of the three mutations, i.e. consistent with the variant α).

Still using the assay to infer the most likely virus lineage causing the infection, we found that samples collected outside hospital settings were less likely to originate from β, γ, or η variants than from the α variant. Finally, in the Hauts-de-France region, we found a temporal increase of β, γ, or η variants compared to the α variant. In most regions, we found a temporal increase of 'other' variants compared to the α variant. This is more difficult to analyse since part of these latter tests are uninterpretable (751/1394, i.e. 54%). Finally, we found a temporal increase of the δ variant compared to the α variant in the regions that were less densely sampled.

Transmission advantages

To further quantify the temporal trends, we performed a statistical analysis using a logistic growth model following previous studies [12, 1, 2, 8]. We found that in Île-de-France the transmission advantage of the positive samples bearing the L452R mutation and neither the E484K nor the E484Q mutations (i.e. potential δ variants) compared to all the other samples was 92% (95% CI: [67,120]%) (Figure 1A).

In Hauts-de-France, we estimated that the transmission advantage of the positive samples bearing the E484K mutation and not the E484Q mutations (i.e. potential β, γ, or η variants) compared to all other samples was 56% (95% CI: [42,71.9]%).

Modeling epidemic scenarios

Using an epidemiological model tailored to the French epidemic [13], we investigated the consequences of our results in the near future. For simplicity, we assumed that vaccine coverage will reach 75% of the whole population by the end of August 2021 and that the lifting of restriction measures or the weather have no effect (see details in the Supplementary Methods). In Figure 2, the three scenarios correspond to the median (B) and 95%CI boundaries (A and C) of the estimated transmission advantage. We find that δ variant has the potential to initiate an epidemic rebound by the end of the summer but Intensive Care Unit (ICU) overload only occurs at the highest end of the transmissibility advantage (scenario C). In all these scenarios, the additional mortality due to the infection remains limited.

Table 1: Factors associated with the detection of potential SARS-CoV-2 variants, as assessed by relative risk ratios using a multinomial log-linear model, France, 31 May-8 June 2021 ($n = 5,061$). See [11] for details about the methods used.

	$\beta/\gamma/\eta$-**like**	δ-**like**	**other**
age	NS [0.97,1.10]	NS [0.94,1.30]	NS [0.98,1.10]
location (non-hospital)	0.54 [0.40,0.74]	NS [0.61,3.80]	NS [0.74,1.30]
date:Normandie	NS [0.89,1.30]	NS [0.65,1.50]	NS [0.95,1.30]
date:Hauts-de-France	1.37 [1.10,1.80]	NS [0.850,2.30]	1.30 [1.10,1.60]
date:Ile-de-France	NS [0.88,1.10]	1.49 [1.20,1.90]	1.10 [1.00,1.20]
date:other	NS [0.87,1.30]	1.68 [1.20,2.30]	1.28 [1.10,1.50]

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 1: **Estimated transmission advantage of the δ variant with respect to all the other lineages in Ile-de-France, 31 May-8 June 2021.** The triangles indicate the generalised linear model (GLM)-fitted values and the line the output of the logistic growth model estimation. The shaded area represents the 95 %CI. The title indicates the estimated transmission advantage of the δ variant over the other lineages.

Discussion

Screening for SARS-CoV-2 mutations bore by the δ variant on samples collected between 31 May and 8 June 2021 indicates that this variant might already be spreading rapidly in the area of Paris, and potentially in other regions of France. According to our estimates, by mid-June 2021 its frequency in the Île-de-France region could already be above 10%.

There are several potential biases to this analysis, which we attempted to correct. First, since our dataset gathers results from local laboratories, there can be delays in data centralisation. To address this, we collected the data available on 16 June 2021, which included tests results as recent as June 14, and only analysed the data up to June 8.

Another potential issue has to do with the specificity of the test used. Our estimated frequency of δ variants, which is in the order of 4% of the positive tests on June 8, is consistent with the outcome of national sequencing studies (0.2% on 11 May 2021 [14]) although with a short doubling time (approximately 8 days). Furthermore, our estimate is conservative since we treat all the samples that are uninterpretable or where the signal is weak as non-δ variant samples.

Regarding the sampling scheme, the French authorities have announced strict monitoring of the spread of the δ variant, which means that contact tracing could be more intense. This could artificially enrich the data in δ variant positive test. We do not know the context in which most tests were performed, except for that in a hospital setting, mainly for hospitalised patients. We expect hospital samples to be less impacted by a potential bias related to contact tracing because, aside from nosocomial infections, the contacts of

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 2: **COVIDSIM projections of the French COVID-19 epidemic for different transmission advantages of the δ variant** The three scenarios use the lower boundary (+67%, A stripes), mean (+92%, B stripes) and upper boundary (+120%, C stripes) of the estimated transmission advantage of the δ variant with respect to all other lineages in Ile-de-France to simulate nationwide epidemiological dynamics. The blue stripes represent the current nationwide COVID-19 ICU bed occupancy while the pink stripes represent the cumulative COVID-19 hospital mortality by the end of 2021. The width of each stripe corresponds to the range spanned by 95% of the associated simulations. The turquoise triangles and the red dots are the rolling 7-day averaged national COVID-19 ICU bed occupancy and cumulative hospital mortality data. The purple dotted horizontal lines show a key ICU capacity threshold highlighted by health authorities (3,000 COVID-19 patients) and the pre-pandemic French ICU capacity, ca. 5000 beds. The orange vertical line indicates the day the simulation was performed.

a hospitalised person are unlikely to be hospitalised. We find no effect of the hospitalisation status in the multinomial model and running the analyses on the hospitalised samples only yielded a similar trend (although with a large 95% CI: 81% [19,166]%).

Finally, our estimation of the transmission advantage assumes that the transmission fitness of the different lineages do not vary over time. This is unlikely to be the case with the ongoing vaccination campaign and the variations in natural immunity. However, the short time period considered for this analysis justifies this assumption.

The estimated transmission advantage in the Île-de-France is higher than that estimated in the UK [6]. One interpretation is that this results from the aforementionned contact-tracing bias. Another interpretation is that the vaccination coverage in France compared to the UK [15]. Indeed, early evidence suggests that the δ variant could be evading immunity more than the α variant [7]. Finally, not that are estimates are consistent with recent transmission advantages from phylodynamics approaches [16].

These results have major public health implications because they imply that variant δ could already be spreading rapidly. In absence of specific interventions and based on the current vaccine rollout, our model tailored to the French epidemic suggests that this could cause another epidemic wave starting in August 2021. The magnitude and exact timing of this wave would depend on the exact transmission advantage of

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

the variant and on the increase in vaccination coverage. Finally, this picture could be further complicated by the spread of other variants since the dominant variant α could be transmitting less than variants β and γ [11].

Acknowledgements

We thank Gilles Roullin, Eric Hedbaut and Virginie Dubois from CERBA for their technical assistance, and the ETE team from CNRS, IRD, and University of Montpellier for discussion.

Conflict of interests

None declared.

Ethical statement

This study has been approved by the Institutional Review Board of the CHU of Montpellier and is registered at ClinicalTrials.gov with identifier NCT04738331.

References

[1] Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;p. eabg3055.

[2] Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;p. 1–17.

[3] Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DdS, Mishra S, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;.

[4] Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438–443.

[5] World Health Organisation. Tracking SARS-CoV-2 variants; 2021. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.

[6] Public Health England. SARS-CoV-2 variants of concern and variants under investigation - Technical briefing 15; 2021. 15. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/993879/Variants_of_Concern_VOC_Technical_Briefing_15.pdf.

[7] Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv. 2021;p. 2021.05.22.21257658.

[8] Haim-Boukobza S, Roquebert B, Trombert-Paolantoni S, Lecorche E, Verdurme L, Foulongne V, et al. Detection of Rapid SARS-CoV-2 Variant Spread, France, January 26–February 16, 2021. Emerg Infect Dis. 2021;27(5):1496–1499.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

[9] Gaymard A, Bosetti P, Feri A, Destras G, Enouf V, Andronico A, et al. Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021. Eurosurveillance. 2021;26(9):2100133.

[10] Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature Microbiology. 2020;5(11):1403–1407.

[11] Roquebert B, Trombert-Paolantoni S, Haim-Boukobza S, Lecorche E, Verdurme L, Foulongne V, et al. The SARS-CoV-2 B.1.351 lineage (VOC β) is outgrowing the B.1.1.7 lineage (VOC α) in some French regions in April 2021. Eurosurveillance. 2021;26(23):2100447.

[12] Chevin LM. On measuring selection in experimental evolution. Biology Letters. 2011;7(2):210–213.

[13] Sofonea MT, Reyné B, Elie B, Djidjou-Demasse R, Selinger C, Michalakis Y, et al. Memory is key in capturing COVID-19 epidemiological dynamics. Epidemics. 2021;p. 100459.

[14] Santé Publique France. Quelle est l'évolution moléculaire des virus SARS-CoV-2 circulant sur le territoire ? Résultats de l'enquête Flash#9;. Accessed on 16 June 2021. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/enquetes-etudes/quelle-est-l-evolution-moleculaire-des-virus-sars-cov-2-circulant-sur-le-terri

[15] Max Roser EOO Hannah Ritchie, Hasell J. Coronavirus pandemic (COVID-19); 2020. Available from: https://ourworldindata.org/coronavirus.

[16] Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Eurosurveillance. 2021;26(24):2100509.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplementary materials

S1 Methods and data

We analyse the qualitative outcome of the SARS-CoV-2 VirSNiP E484Q/K and L452R assay from Tib Mol Biol performed on samples that tested positive for SARS-CoV-2 in partner laboratories, mainly using partly the PerkinElmer SARS-CoV-2 Real-time RT-PCR Assay (Perkin Elmer).

The VirSNiP test targets three mutations specifically (E484K, E484Q, and L462R). Based on the genomics of the different lineages and their prevalence in France, the test results are interpreted as follows:

- E484K-/E484Q-/L462R-: potential infection by the α variant
- E484K-/E484Q-/L462R+: potential infection by the δ variant
- E484K+/E484Q-/L462R-: potential infection by the β, γ, or η variant

All the other combinations were rare and grouped in the "other" category (see below for the details).

The data was extracted on June 16, 2021 and the most recent test results were from June 14, 2021. However, to correct for potential delays in the recording of the results from local partners, we did not include any tests performed after June 8, 2021. We also only included from individuals from 5 to 80 years old, and included at most one sample per individual.

The statistical methods are described in details in [11]. The data and R script used will be provided upon publication.

S2 Data characteristics

The characteristics of the data are shown in Table S1.

Table S1: Characteristics of the samples analysed via the VirSNiP assay, France, 31 May-8 June 2021 ($n = 5,061$).

Characteristics		**Value**
Age	*median [min,max]*	34 [5,80]
Sample origin	general population	4775 (94.3%)
	hospital	286 (5.7%)
Sampling date	*median [min,max]*	June 3 [May 31, June 8]
Region	Ile-de-France	2443 (48.7%)
	Normandie	946 (18.9%)
	Hauts-de-France	611 (12.2%)
	other	1014 (20.2%)
Test result	alpha-like	2833 (56.0%)
	beta/gamma/B.1.525-like	695 (13.7%)
	delta-like	139 (2.7%)
	other	1394 (27.5%)

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Among the 'other' test results, the majority corresponded to uninterpretable test results (751/1394, i.e. 54%) and a large fraction to tests without the L452R mutant and an ambiguity for the E484 mutation (524/1394, i.e. 38%), which could be indicative of an infected by a β, γ, or η variant with a low virus load. Note that this assumption is conservative to avoid overestimating the spread of the δ variant. In fact, some of the tests in the 'other' category (74/1394, i.e. 5%) find a clear signal for the L452R mutation with an ambiguity regarding the E484 mutation and could, therefore, be associated with this variant.

S3 Epidemiological model

The epidemiological model used to simulate the scenarios shown in Figure 2 is based on the discrete-time framework adjusted to the French epidemic the methodology of which is detailed in [13]. The original model was extended to take into account the vaccine rollout, the extrapolation of which was based on official planned doses shipments.

We made the simplifying and optimistic assumption that the vaccine prevents 90% of critical infections and 80% of secondary infections from the day of the first dose injection, while we assumed natural immunity to prevent 84% of reinfections.

S4 Supplementary Results



Figure S1: **Estimated transmission advantage of the β, or γ, or η variant with respect to all the other lineages in Hauts-de-France, 31 May-8 June 2021.** The triangles indicate the GLM-fitted values and the line the output of the logistic growth model estimation. The shaded area represents the 95 %CI. The title indicates the estimated transmission advantage of the δ variant over the other lineages.